A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502647-35-00

Acronym

MK-6024-013

Enrollment

Registered

2023-08-21

Start date

2023-09-01

Completion date

2025-12-29

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic steatohepatitis

Brief summary

Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 52, Percentage of Participants Who Experienced an Adverse Event (AE), Percentage of Participants Who Discontinuing Study Medication Due to an AE

Detailed description

Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis At Week 52, Change from Baseline in Body Weight At Week 52

Interventions

DRUGefinopegdutide

DRUGSEMAGLUTIDE

DRUGMK-6024_PBO_0.5mL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 52, Percentage of Participants Who Experienced an Adverse Event (AE), Percentage of Participants Who Discontinuing Study Medication Due to an AE	—

Secondary

Measure	Time frame
Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis At Week 52, Change from Baseline in Body Weight At Week 52	—

Countries

Austria, Belgium, Czechia, France, Hungary, Italy, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026